HIV and Oral Health 101

Mark Schweizer, DDS MPH
Director of Development and Special Projects
Nova Southeastern University College of Dental Medicine
Dental Director South Florida Southeast AIDS Education and Training Center
Disclosures

- The activity planners and speakers do not have any financial relationships with commercial entities to disclose.
- The speakers will not discuss any off-label use or investigational product during the program.
- This slide set has been peer-reviewed to ensure that there are no conflicts of interest represented in the presentation.
Objectives

- Identify the current demographics of HIV/AIDS and infections rates
- Understand the disease course of HIV/AIDS
- Understand the Current Diagnostic Test of HIV/AIDS
- Understand Oral Manifestations of HIV, their Significance and Treatment
- Explain the HIV Continuum of Care and the Role of the Dental Professional
- Describe current medication regiments and their side effects
- Understand PrEP
- Understanding PEP
In 2016, an estimated 41,900 people were diagnosed with HIV infection in the United States.

More than 1.2 million people in the US are living with HIV, and 1 in 7 of them don’t know it.

Over the last decade, the annual number of new HIV diagnoses declined 19%.

Gay and bisexual men accounted for an estimated 83% (29,418) of HIV diagnoses among males and 67% of all diagnoses.

Black/African American gay and bisexual men accounted for the largest number of estimated HIV diagnoses (11,201), followed by white gay and bisexual men (9,008).

http://www.cdc.gov/hiv/statistics/overview/ataglance.html
2,800 (7%) among people who inject drugs*

8,600 (23%) among heterosexuals

26,200 (70%) among gay and bisexual men
HIV in the United States

- Heterosexuals and people who inject drugs also continue to be affected by HIV.
- Heterosexual contact accounted for 24% (10,527) of estimated HIV diagnoses.
- Women accounted for 19% (8,328) of estimated HIV diagnoses. Diagnoses among women are primarily attributed to heterosexual contact or injection drug use.
- An estimated 7% (2,635) of HIV diagnoses were attributed to injection drug use.

http://www.cdc.gov/hiv/statistics/overview/ata glance.html
HIV in North Carolina

Key Points from 2016 North Carolina HIV/STD Surveillance Report:
• As of December 31, 2016, the number of people diagnosed with HIV who reside in North Carolina (including those initially diagnosed in another state) was 34,187. 3400 are unaware of their infection.
• In 2016, 1,399 new diagnoses of HIV were reported among the adult and adolescent (over 13 years old) population, at a rate of 16.4 per 100,000 population. This is a slight increase from 2015, where 1,334 persons were newly diagnosed with HIV, at a rate of 15.9 per 100,000 population.
• There were two infants with perinatal (mother-to-child) transmission of HIV in 2016.
North Carolina HIV Infection Rates by Year of Diagnosis 2000-2016

*Based on most recent address in eHARS as of December 31 of the given year.
**New cases are only among adults and adolescents (13 years and older).
Age Distribution of People Diagnosed with HIV and Living in NC* in 2016

Number of Cases

Age at Diagnosis (Year)

- Less than 13
- 13-14
- 15-19
- 20-24
- 25-29
- 30-34
- 35-39
- 40-44
- 45-49
- 50-54
- 55-59
- 60-64
- 65 and Older

*Based on most recent address in eHARS as of December 31, 2016

Data Source: enhanced HIV/AIDS Reporting System (eHARS) (data as of June 27, 2017).
Newly Diagnosed HIV among Adult/Adolescents (13 years and older) by Gender
North Carolina, 2000-2016

Data Source: enhanced HIV/AIDS Reporting System (eHARS) (data as of June 27, 2017).
Newly Diagnosed HIV Cases among Adults/Adolescents by Race/Ethnicity

HIV Cases: 1,399
- 24% Black/African American*
- 62% White/Caucasian*
- 10% Hispanic/Latino
- 1% Asian and Pacific Islander*
- 1% American Indian/Alaska Native*
- 2% Multiple Race

North Carolina Population: 8,507,543**
- 22% Black/African American*
- 67% White/Caucasian*
- 8% Hispanic/Latino
- 1% Asian and Pacific Islander*
- 1% American Indian/Alaska Native*
- 3% Multiple Race

**US Census Bureau North Carolina 2016 Adult and Adolescent population estimate
*Non-Hispanic/Latino
Data Source: enhanced HIV/AIDS Reporting System (e-HARS) (data as of June 27, 2017).
Newly Diagnosed HIV Rates by County
North Carolina, 2016
Hierarchical Risk\(^a\) for HIV Exposure among Newly Diagnosed HIV Rates among Adults
North Carolina 2016

\[ N = 1,399 \]

- MSM 65%
- Heterosexual 29%
- MSM/IDU 3%
- IDU 3%
- Unknown risk has been redistributed.

Data Source: enhanced HIV/AIDS Reporting System (eHARS) (data as of June 27, 2017).
What is HIV?

HIV stands for 'human immunodeficiency virus'. There are two types of HIV, HIV-1 and HIV-2. In the United States, unless otherwise noted, the term “HIV” primarily refers to HIV-1. HIV is a virus (of the type called retrovirus) that infects cells of the human immune system (mainly CD4 positive T cells).

Immunodeficient people are more susceptible to a wide range of infections, most of which are rare among people without immune deficiency.

Infections associated with severe immunodeficiency are known as 'opportunistic infections', because they take advantage of a weakened immune system.
What is AIDS

T-Cell count less than 200
→ 80% of patients with counts below this level will develop AIDS within 3 years in the absence of treatment.

Candidiasis, CMV, Herpes Simplex, Histoplasmosis, Wasting syndrome, Kaposi’s sarcoma, Tuberculosis, Lymphoma, is Pneumocystis jirovecii pneumonia (PJP)
Etiology

• HIV is a retrovirus, depends upon a unique enzyme, reverse transcriptase, to replicate within host cell.

• The HIV genomes contain genes for three basic structural proteins and at least 5 other regulatory proteins.

• The greatest variability in strains of HIV occurs in the viral envelope.
Modes of Transmission

Only certain body fluids—blood, semen (cum), pre-semenal fluid (pre-cum), rectal fluids, vaginal fluids, and breast milk—from a person who has HIV can transmit HIV. These fluids must come in contact with a mucous membrane or damaged tissue or be directly injected into the bloodstream (from a needle or syringe) for transmission to occur. Mucous membranes are found inside the rectum, vagina, penis, and mouth.

In the United States, HIV is spread mainly by

• Having anal or vaginal sex with someone who has HIV without using a condom or taking medicines to prevent or treat HIV.
  • For the HIV-negative partner, receptive anal sex (bottoming) is the highest-risk sexual behavior, but you can also get HIV from insertive anal sex (topping).
  • Either partner can get HIV through vaginal sex, though it is less risky for getting HIV than receptive anal sex.
Modes of Transmission

- Sharing needles or syringes, rinse water, or other equipment (works) used to prepare drugs for injection with someone who has HIV.

Less commonly, HIV may be spread
- From mother to child during pregnancy, birth, or breastfeeding. Although the risk can be high if a mother is living with HIV and not taking medicine, recommendations to test all pregnant women for HIV and start HIV treatment immediately have lowered the number of babies who are born with HIV.
- By being stuck with an HIV-contaminated needle or other sharp object. This is a risk mainly for health care workers.
- Having another sexually transmitted disease (STD) can increase the risk of getting or transmitting HIV.
Modes of Transmission/Health Care Workers

The average risk of HIV infection after a needle stick or cut exposure to HIV-infected blood is 0.3% (i.e., three-tenths of one percent, or about 1 in 300). Stated another way, 99.7% of needle stick/cut exposures do not lead to infection.

The risk after exposure of the eye, nose, or mouth to HIV-infected blood is estimated to be, on average, 0.1% (1 in 1,000).

The risk after exposure of non-intact skin to HIV-infected blood is estimated to be less than 0.1%. A small amount of blood on intact skin probably poses no risk at all. There have been no documented cases of HIV transmission due to an exposure involving a small amount of blood on intact skin (a few drops of blood on skin for a short period of time).

There is only a single documented risk of occupational exposure since 1999 and no reported dental exposure since 1998.
Post-exposure Prophylaxis

- Non-occupational N-PEP
- Occupational Exposure O-PEP

**PEP should be considered if you’ve had a recent possible exposure to HIV at work. Report your exposure to your supervisor, and seek medical attention immediately.**

- Occupational transmission of HIV to health care workers is extremely rare, and the proper use of safety devices and barriers can help minimize the risk of exposure while caring for patients with HIV.

- A health care worker who has a possible exposure should see a doctor or visit an emergency room immediately.

- PEP must be started within 72 hours after a recent possible exposure to HIV. The sooner, the better; every hour counts.

PEPline (1-888-448-4911), which offers around-the-clock advice on managing occupational exposures to HIV, as well as hepatitis B and C. Exposed health care workers may also call the PEPline, but they should seek local medical attention first.
HIV Transmissions in the Dental Office

Universal Precautions

- Mask
- Gloves
- Eye Protection with Face Shield or side protectors
- Disposable Gowns
- Needle Protectors
- Bur Protectors

- No open toe shoes
- Bare legs
HIV Testing in the Oral Health Setting

Medical Model of Care
Importance of Early Diagnosis and Treatment

To facilitate early diagnosis and treatment, the Centers for Disease Control and Prevention (CDC) issued revised recommendations for widespread HIV testing. The new recommendations proposed that HIV testing be offered to all individuals, ages 13 to 64, in all healthcare settings on an “opt-out” basis, rather than waiting for patients to request testing. These revisions brought HIV testing in line with other STI protocols and helped reduce what had been referred to as “HIV exceptionalism.”

Participants were very positive about being offered rapid oral HIV testing in the dental clinic setting and thought it consistent with their view of dental practice.

Diagnosis

Blood tests are the most common way to diagnose HIV. These tests look for antibodies to the virus that the body creates in an attempt to fight the virus.

People exposed to the virus should get tested immediately, although it can take the body anywhere from six weeks to a year to develop antibodies to the virus. Follow-up tests may be needed depending on the initial time of exposure.

Early testing is crucial. If you test positive for the virus, you and your doctor will discuss and develop a treatment plan that can help fight HIV and ward off complications. Early testing also can alert you to avoid high-risk behavior that can spread the virus to others.
Diagnosis

• ELISA Test — ELISA, which stands for enzyme-linked immunosorbent assay, is used to detect HIV infection. If an ELISA test is positive, the Western blot test is usually administered to confirm the diagnosis. If an ELISA test is negative, but you think you may have HIV, you should be tested again in one to three months.

ELISA is quite sensitive in chronic HIV infection, but because antibodies aren't produced immediately upon infection, you may test negative during a window of a few weeks to a few months after being infected. Even though your test result may be negative during this window, you may have a high level of the virus and be at risk of transmitting infection.
Diagnosis

• Home Tests Saliva Tests — A cotton pad is used to obtain saliva from the inside of your cheek. The pad is placed in a vial and submitted to a laboratory for testing. Results are available 45 minutes. Positive results should be confirmed with a blood test.

• Viral Load Test — This test measures the amount of HIV in your blood. Generally, it's used to monitor treatment progress or detect early HIV infection. Three technologies measure HIV viral load in the blood: reverse transcription polymerase chain reaction (RT-PCR), branched DNA (bDNA) and nucleic acid sequence-based amplification assay (NASBA). The basic principles of these tests are similar. HIV is detected using DNA sequences that bind specifically to those in the virus. It is important to note that results may vary between tests.

• Western Blot — This is a very sensitive blood test used to confirm a positive ELISA test result.
Clinical Course

• The complications of HIV-related infections affect virtually every organ

• The CD4 lymphocyte count provides very important prognostic information

• Many individuals with HIV infection remain asymptomatic for years, even without anti-retroviral therapy.

• The mean time between the exposure and the development of AIDS is approximately 10 years.

• Physical examination may be entirely normal.

• Abnormal finding range from non-specific to highly specific for HIV infection
Diagnosis/Lab Findings

Nonspecific findings with HIV infection may include anemia, leukopenia, thrombocytopenia, elevation of ESR and hypocholesterolemia

Laboratories to provide prognostic information and guide therapy

• Absolute CD4 lymphocyte count → most widely used predictor of HIV progression.

• HIV viral load test: measure the amount of actively replicating HIV virus, correlates with disease progression and response to medications.

• ANC (Absolute Neutrophil Count): measure the level of immunosuppression, correlates with the risk of opportunistic infections.
<table>
<thead>
<tr>
<th>LAB TESTS FOR HIV STATUS</th>
<th>NORMAL RANGE</th>
<th>TREATMENT CONSIDERATION</th>
<th>MEDICAL SIGNIFICANCE</th>
<th>DENTAL SIGNIFICANCE</th>
<th>CRITICAL VALUES RECOMMENDED MEDICAL CONSULTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV VIRAL LOAD</td>
<td># of HIV RNA copies per ml of blood</td>
<td>Can be &lt;20 copies/mL on commercially available tests Uncontrolled HIV up to 750,000</td>
<td>If &gt; 20 copies/mL Should be under copies/mL If over 6 months on ART</td>
<td>Indicates rate of HIV progression and ART response</td>
<td>Predictor of oral manifestation including Candidiasis Xerostomia, Recurrent Caries, cancer, etc. If &gt; 20 copies per mL after 6 months of ART</td>
</tr>
<tr>
<td>CD4 HELPER T CELL COUNT</td>
<td>T-lymphocytes/mm³ (absolute T-cell count)</td>
<td>500-1500 ART recommended for all HIV infected patients regardless of CD4 cell count</td>
<td>&lt;200 = AIDS Defining</td>
<td>Indicates immune status &amp; determines therapy irrespective of total Lymphocyte</td>
<td>In general, HIV disease is progressing if the CD4 count is going down. IF &lt; 200 after 6 months of ART</td>
</tr>
<tr>
<td>ANC</td>
<td>(Absolute Neutrophil Count) NEUTROPHIL % X WBC COUNT</td>
<td>1500 to 8000</td>
<td>&lt; 500 requires premedication</td>
<td>Susceptibility to infection</td>
<td>Susceptibility to infection</td>
</tr>
</tbody>
</table>
Antibiotic prophylaxis in neutropenic patients reduces mortality, febrile episodes, and bacterial infections

Antibiotic coverage, prior to procedures likely to cause bleeding and bacteremia, is recommended for the immunocompromised HIV-infected patient when the neutrophil count drops below 500 cells/mm3 (neutropenia). Patients at this advanced stage of disease may already be taking antibiotics to prevent opportunistic infection, therefore, additional medications may not always be required. However, when antibiotic coverage is indicated, regimens similar to those for the prevention of bacterial endocarditis are considered effective.

OVERVIEW AND UPDATES OF CURRENT PREFERRED ART FOR TREATMENT OF HIV
New: When to Start ART?

Panel's Recommendations for Initiating Antiretroviral Therapy in Treatment–Naive Patients

Panel's Recommendations

- Antiretroviral therapy (ART) is recommended for all HIV-infected individuals, regardless of CD4 T lymphocyte cell count, to reduce the morbidity and mortality associated with HIV infection ([A1]).
- ART is also recommended for HIV-infected individuals to prevent HIV transmission ([A1]).
- When initiating ART, it is important to educate patients regarding the benefits and considerations regarding ART, and to address strategies to optimize adherence. On a case–by–case basis, ART may be deferred because of clinical and/or psychosocial factors, but therapy should be initiated as soon as possible.

Goals for Treatment of HIV

- Suppress viral replication
  - Elimination is not possible with current therapies
  - Maximal suppression of viral replication (reduce transmission)
    - Goal of undetectable HIV RNA concentrations < 20-75 copies or “undetectable”
      - Even if viral load is undetectable, the patient is contagious (less risk of transmission with undetectable viral load)
- Restore & preserve immune function
  - Prevent opportunistic infections
  - ↑ immune function (CD4 count) correlates with ↓ viral replication
- Minimize adverse effects and avoid development of drug resistance
- Improve quality of life
- ↓ morbidity & mortality
Basics in approach to HIV treatment

- HIV RNA levels (Viral Load) & CD4 lymphocyte counts
  - Determine disease progression/response to treatment
- Regimen selection is also based on antiretroviral status
  - Treatment naïve
  - Previous treatment/failure and resistance profiles
- Current therapies cannot eradicate the virus
  - Pools of latently infected CD4 cells are established soon after acute infection and have a long half-life
  - No cure available currently
The HIV Life Cycle

1. **Binding (also called Attachment):** HIV binds (attaches itself) to receptors on the surface of a CD4 cell.

2. **Fusion:** The HIV envelope and the CD4 cell membrane fuse (join together), allowing HIV to enter the CD4 cell.

3. **Reverse Transcription:** Inside the CD4 cell, HIV releases and uses reverse transcriptase (an HIV enzyme) to convert its genetic material—RNA—to double-stranded DNA. The conversion of HIV RNA to HIV DNA allows HIV to enter the CD4 cell nucleus and combine with the cell's genetic material—cell DNA.

4. **Integrase:** Inside the CD4 cell nucleus, HIV releases integrase (an HIV enzyme). HIV uses integrase to insert (integrate) its viral DNA into the DNA of the CD4 cell.

5. **Replication:** Once integrated into the CD4 cell DNA, HIV begins to use the machinery of the CD4 cell to make long chains of HIV proteins. The protein chains are the building blocks for more HIV.

6. **Assembly:** New HIV proteins and HIV RNA move to the surface of the cell and assemble into immature (uncapsidated) HIV.

7. **Budding:** Newly formed immature (noninfectious) HIV pushes itself out of the host CD4 cell. The new HIV releases protease (an HIV enzyme). Protease helps to break up the long protein chains that form the immature virus. The smaller HIV proteins combine to form mature (infectious) HIV.

HIV medicines in six drug classes stop HIV at different stages in the HIV life cycle:

- **Integrase inhibitors**
- **Reverse transcriptase inhibitors**
- **Protease inhibitors**
- **Fusion inhibitors**
- **Non-nucleoside reverse transcriptase inhibitors (NNRTIs)**
- **罩核苷酸逆转录酶抑制剂(PIs)**
Classes of ART

- Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
- Integrase Strand Transfer Inhibitor (INSTIs)
- *Protease Inhibitors (PIs)*
- Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Entry inhibitors: Fusion Inhibitors and CCR5 antagonist

*PIs may be a good choice for certain patient populations
Bold indicates part of a preferred therapy regimen
# Preferred Regimens

## Integrase Strand Transfer Inhibitor Based Regimen

<table>
<thead>
<tr>
<th></th>
<th>TRUVADA® OR DESCOVY®</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISENTRESS®</td>
<td></td>
</tr>
<tr>
<td>STRIBILD®*</td>
<td></td>
</tr>
<tr>
<td>GENVOYA®*</td>
<td></td>
</tr>
<tr>
<td>TIVCAY®</td>
<td></td>
</tr>
<tr>
<td>TRUVADA® OR DESCOVY®</td>
<td></td>
</tr>
<tr>
<td>TRIUMEQ®+</td>
<td></td>
</tr>
</tbody>
</table>

* Contain cobicistat (booster)

+ Requires HLA-B* 5701 Screening
Preferred/Recommended ART (Antiretroviral therapy)
Specific populations

<table>
<thead>
<tr>
<th>Protease-Inhibitor Based Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prevista</strong></td>
</tr>
<tr>
<td>Norvir cobicistat</td>
</tr>
<tr>
<td>(as booster)</td>
</tr>
<tr>
<td>Tenofovir</td>
</tr>
<tr>
<td>Emtricitabine</td>
</tr>
</tbody>
</table>

- The rate of transmitted PI resistance is low due to a high genetic barrier and low rates of treatment emergent resistance
- Clinicians may initiate a PI based regimen in individuals with uncertain adherence
- Using a protease-inhibitor may be preferred in the following cases where treatment needs to begin before resistance testing results are available
  - During acute HIV infection
  - Pregnancy
  - Certain Opportunistic infections
Adverse Effects of Commonly Prescribed ART
- Xerostomia
- Bone mineral density reduction
- Insomnia
- Rash
- Nausea
- Diarrhea
Resources for checking interactions

  - HIV iChart app available
- DHHS Adult HIV Guidelines, Tables 17-20
  [www.aidsinfo.nih.gov]
Oral Health and HIV

• 90% of PLWHAs have at least one chronic oral condition

• 32-46 percent of PLWHAs will have at least one major HIV-related oral health problem.

• 58-68 percent PLWHAs do not receive regular health care.

http://hab.hrsa.gov/about/has/files/oral_health_fact_sheet.pdf
Oral Health and HIV

- Barriers PLWHA face in receiving oral health care include lack of insurance, limited incomes, lack of providers, stigma, and limited awareness.

- Poor oral health can impede food intake and nutrition, leading to poor absorption of HIV medications and leaving PLWHA susceptible to progression of their disease.4

- HIV medications have side effects such as dry mouth, which predisposes PLWHA to dental decay, periodontal disease, and fungal infections.

Oral Health and HIV

Health People 2020
• Increase awareness of the importance of oral health to overall health and well-being.
• Increase acceptance and adoption of effective preventive interventions.
• Reduce disparities in access to effective preventive and dental treatment services.

Oral Health and HIV

HAB’s Oral Health Performance Measures

- Dental and medical history
- Dental treatment plan Oral health education
- Periodontal screening or examination
- Phase I treatment plan completion (prevention, maintenance, elimination of oral health disease)

http://hab.hrsa.gov/deliverhivaidscare/habperformmeasures.html
Oral Manifestations of HIV

Significant of Oral Manifestations

- First sign of clinical disease
- Signify disease progression
- Signify possible ART failure
- Effects on medication adherence and nutrition
Oral Manifestations of HIV

In the Era of ART

Decreasing:
- Candidiasis
- Necrotizing Gingivitis
- Kaposi’s Sarcoma
- Oral Hairy Leukoplakia

Increasing:
- Dental Decay/Periodontal Disease
- Oral HPV
XEROSTOMIA
There are multiple causes of xerostomia:

• Anticholinergic effects of many medications
• Alcohol and drug abuse
• Damaging head and neck radiation
• Comorbidities from HIV/AIDS such as cardiac disease, diabetes, and mental health disorders which occurs in PLWHA. As a result, many of the medications especially the antidepressants, anxiolytics, diuretics, and antihistamines being taken for these comorbidities

There are still differing studies of the xerostomic effects of antiretroviral medications used to treat HIV.
Xerostomia is the subjective complaint of oral dryness. This must be distinguished from salivary gland dysfunction which is an objective disease characterized by reduced salivary flow. Studies have shown that 40% or more of PLWHA experience major xerostomia during their disease. Studies of PLWHA with xerostomia show a frequently negative effect on their quality of life.

Symptoms of xerostomia include cracked peeled atrophic lips, glossitis, and pale dry buccal mucosa. Xerostomia can lead to dysphagia, oral pain of unknown origin, dental caries, oral infections, periodontal disease, angular cheilitis associated with candidiasis and can affect the health-related quality of life. These features of xerostomia can lead to the inability of the patient to take necessary medications, and can influence intake of proper nutrients, leading to malnutrition and a decline in overall health.
More significant in the era of ART is the increase in prevalence of salivary gland disease. Salivary gland disease can arise in 4% to 10% of adults and children with HIV.

HIV salivary gland disease (HIV-SGD) is a distinct disorder characterized by persistent major salivary gland swelling and xerostomia. Most commonly affected is one or both parotid glands sometimes which will occur without xerostomia. In some cases, salivary gland enlargement may be the first clinical manifestation of HIV infection, but more often a sign of late HIV infection.

The exact pathophysiology of HIV-SD, origins include lymphoepithelial lesions, cysts, intraglandular lymph nodes, and an inflammatory infiltrate similar to what is often observed in Sjogren’s syndrome however with distinct histopathologic and serological differences. In the infiltrate, there are persistent circulating CD8+ lymphocytosis and diffuse visceral CD8+ lymphocytic infiltration.
Treatment for Xerostomia

Salivary stimulants such as sugarless gum or sugarless candies may provide relief. Candies that are acidic should be avoided as frequent use may lead to loss of tooth enamel

- Biotene, Eclipse, Extra, Orbit

Salivary substitutes
- Biotene Oral Balance, Biotene Moisturizing Mouth Spray
- Salivart (Xenex), Oralube(Xenex), Xerolube Colgate), Plax (Pfizer)

Pharmacologic Stimulants
- Pilocarpine HCl, Cevimeline HCl (Caution with Beta Blockers)

An increase in caries can occur, so fluoride rinses (that can be bought over the counter) or prescription fluorides should be used daily, and visits to the dentist should occur two to three times per year.

- OTC products (.05% NaF) ACT, Fluoroguard
- Prescription products
  - Prevident 5000 plus toothpaste/gel/rinse, Fluoride Varnish

Home Care Instructions
- Brush, Floss, Tongue Scraper
Dental Decay

Factors that Increase Dental Decay

• Xerostomia is moderate to severe in 30-40% living with HIV/AIDS
• Xerostomia is caused by many medications used to treat HIV and comorbidities related to both HIV and aging
• In addition, the HIV virus affects the salivary glands, leading to salivary gland deformities and damages that also decrease salivary flow.
• Diet
• Substance Abuse
• Increased Life Expectancy
Periodontal Disease

Links between Periodontal Disease and other disease states: Diabetes, Heart Disease, Strokes
Periodontal Disease in the Era of ART
Shift of prevalence towards periodontal diseases.
Lack of oral hygiene determined by plaque formation and reduced CD4-counts with pronounced periodontal inflammation can be seen as risk factors for periodontal disease. There is an increase in periodontal inflammation markers in patients with HIV.
Increased Prevalence of periodontal diseases in HIV-infected patients on antiretroviral therapy.
Overall high prevalence of manifestations underlines the importance of oral examination for the general practitioner and visits by oral specialists should become a routine procedure in HIV-patients care.

Periodontal Disease

Linear Erythematous Gingivitis This entity appears as a 1 -3mm band of marginal gingival erythema, often with petechiae. It is typically associated with no symptoms or only mild gingival bleeding and mild pain.

Histological examination reveals an incomplete or aborted inflammatory response with principally hyperemia present.

Oral rinsing with chlorhexidine gluconate 0.12% often reduces or eliminates the erythema and typically requires prophylactic use to avoid recurrence.
Periodontal Disease

• Amoxicillin 250mg 3 x/day with Metronidazole 250mg 3X/day x 5-7 days
• Antimicrobial rinses (0.12% Chlorhexidine) 15cc 2xday x 14 days
• Concurrent Antifungal maybe necessary
• Referral for immediate dental care
• Stress oral home care for clients and routine dental care
Human Papilloma Virus

- About 7% of Americans have oral HPV. That's far fewer than the number who have the genital version, which is the most common sexually transmitted disease in the U.S.
- Every day in the US, about 12,000 people ages 15 to 24 are infected with HPV. Approximately 26 million Americans on any given day have an oral HPV infection. Of those approximately 2600 are HPV16 the strain that can lead to oral cancer.
- The vast majority of individuals will clear the virus naturally through their own immune response, and never know that they were exposed or had it.

Human Papilloma Virus

More than 40 types of HPV can infect people, but only a few cause cancer. One of the types that causes most cervical cancers, called HPV16, is also linked with most HPV-related head and neck cancers. Oral warts are caused by human papillomavirus (HPV) and may appear anywhere within the oral cavity or on the lips. They occur more frequently and more extensively in people with HIV infection than in those with normal immune function, especially in patients with advancing immune suppression (CD4 counts of <200-300 cells/µL). Oral warts may be refractory to therapy. The frequency of oral warts may increase, at least temporarily, in patients treated with antiretroviral therapy.

Human Papilloma Virus

- Possible spread through Oral Sex and French Kissing

http://saude-joni.blogspot.com/2012/02/hpv-oral.ht
HPV vaccine is recommended for routine vaccination at age 11 to 12 years.
Recommends vaccination for females aged 13 through 26 and males aged 13 through 21 years not vaccinated previously.
Vaccination is also recommended through age 26 years for men who have sex with men and for immunocompromised persons (including those with HIV infection) if not vaccinated.

www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a3.htm
Oropharyngeal Candidiasis (OPC)

The most common HIV related oral lesion is Candidiasis, predominantly due to infection by Candida albicans.

Non albicans species such as C. glabrata, C. tropicalis, C. krusei and C. kefyr have been reported in 1% to 20% of HIV infected patients.

It is often the initial manifestation of symptomatic infection with HIV, and may simply imply concurrent esophageal candidiasis, which is an AIDS indicator lesion, or also be a predictor of the likelihood of other opportunistic infections.

Oropharyngeal Candidiasis (OPC)

Pseudomembranous candidiasis: Acknowledged as the most common variant, it presents as creamy, white, curd like plaques on the oral mucosa or tongue which can be wiped away, leaving a red erythematous surface. Patients may complain of soreness or burning in the mouth.
Erythematous candidiasis

Hypertrophic Candidiasis

Angular Cheilitis
Oropharyngeal Candidiasis (OPC) Treatment

Early treatment of oral candidiasis is warranted not only because of the discomfort caused by the lesions, but also because the foci may act as reservoirs of organisms for local spread of disease.

It takes longer to eradicate candidiasis in HIV infected population, and relapse rates are high.

High fungal counts and smoking appear to increase the tendency for poor response.

Use of topical agents for treatment of OPC is recommended as initial therapy, more so owing to concerns of drug interactions between systemic antifungals and antiretroviral therapy.
Oropharyngeal Candidiasis (OPC) Treatment

Topical antifungal agents include nystatin, clotrimazole, amphotericin B which can be delivered as oral suspensions, troches or tablets. Systemic therapy with ketoconazole, fluconazole, or Itraconazole is indicated in recurrent cases.

Recommend 200mg once daily oral dose of Nizoral (ketoconazole) for resolution of oral signs and symptoms. Although fluconazole is an effective mucosal antifungal drug, candidal recurrence and resistance to fluconazole appear to be an emerging problem.

Hairy leukoplakia (also known as oral hairy leukoplakia, or HIV-associated hairy leukoplakia), is a white patch on the side of the tongue with a corrugated or hairy appearance. It is caused by Epstein-Barr virus (EBV) and occurs usually in persons who are immunocompromised especially those with HIV/AIDS. This white lesion cannot be scraped off. The lesion itself is benign and does not require any treatment, although its appearance may have diagnostic and prognostic implications for the underlying condition.
Oral Hairy Leukoplakia

It is diagnosed by the clinical appearance as asymptomatic, adherent, flat or vertically correlated whitish grey lesions on dorsum of tongue, usually on lateral borders. They often have a shaggy, corrugated or “hairy” appearance. These have been associated with immune suppression, as evidenced by reduced CD4+ cell counts and viremia measured by high HIV RNA level in plasma. These lesions have been shown to predict progression to AIDS even independent of CD4+ count.

Self-limiting and generally requires no treatment.
Oral Hairy Leukoplakia

Diagnosis
- Clinical findings
  - Biopsy-cellular nuclear changes (acanthosis, Cowdry type A inclusions, ground glass and nuclear beading), absence of an inflammatory infiltrate, regions of ballooning cells, and epithelial hyperplasia

Treatment
- Usual resolution with ARV
- Valacyclovir
- Podophyllin resin combined with acyclovir cream
- Oral Hairy Leukoplakia is a manifestation of later HIV disease and an important sign of immunosuppression

In patients living with HIV/AIDS good oral health care is especially important because:

1. Oral manifestations are common in people with HIV infection. More than 90% of HIV infected patients are seen to have at least one HIV related oral manifestation.

2. Oral lesions may be an early indicator of decline in immune function and may warrant further investigations.

3. Control of focal infection within the oral cavity may retard adverse consequences such as progression to systemic diseases.

4. Poorly functioning dentition can adversely affect quality of life, and exacerbate weight loss in HIV infected patients, who may already be malnourished.
Combination ART has been documented to play a critical role in the prevention of oral manifestations of HIV because of its role in the reconstitution of the immune system.

The escalating number of patients infected with HIV and the resulting cases of AIDS has produced an increased observation of oral manifestations associated with this syndrome.

Thus, in addition to comprehensive general health care, oral health care is integral in the management of patients with HIV infection.

The need is comprehensive quality dental care in a multidisciplinary setting with medical and social support providers as poor oral health care in these patients can complicate the management of systemic conditions, lead to nutritional deficiencies, affect antiretroviral treatment compliance and adversely affect quality of life.
Oral health professionals can work with clients to engage them in regular HIV primary medical care and dental care and address issues such as nutrition and treatment compliance.

Accessed March 28, 2016
Number and Percentage of Persons Diagnosed and Living with HIV (PLWH) Engaged in Selected Stages of the Continuum of HIV Care

Florida


<table>
<thead>
<tr>
<th>Stage of Care</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Diagnosed (PLWH) Through 2014</td>
<td>109,969</td>
<td>100%</td>
</tr>
<tr>
<td>Ever in Care</td>
<td>99,516</td>
<td>90%</td>
</tr>
<tr>
<td>Retained in Care IN 2014</td>
<td>78,124</td>
<td>70,287 (64%)</td>
</tr>
<tr>
<td>On ART IN 2014</td>
<td>74,218</td>
<td>67%</td>
</tr>
<tr>
<td>Suppressed Viral Load (&lt;200 copies/ML) IN 2014</td>
<td>64,230</td>
<td>58%</td>
</tr>
</tbody>
</table>
Number and Percentage of Persons Diagnosed and Living with HIV (PLWH) Engaged in Selected Stages of the Continuum of HIV Care

Florida Oral Health Care

- Diagnosed: 82%
- Linked to Care: 66%
- Retained in Care: 85%
- Prescribed ART: 95%
- Virally Suppressed: 95%
Risk Factors for Oral Health Lesions

Moderate and severe degrees of immunodeficiency and detectable viral loads were risk factors for the onset of oral lesions, irrespective of the use of ART.

A mild immunologic impairment (CD4+ 350 to 500 cells/mm$^3$) was sufficient to increase the risk of developing Hairy Leukoplakia nearly 11-fold and shows that immunologic deficiency could be considered to be an independently associated risk factor for the onset of these lesions.

A detectable VL (> 50 copies/mm$^3$) was a risk factor for Oral Candidiasis compared with undetectable circulating HIV-RNA. When this association is investigated together with CD4+ counts and use of ART in detectable VL did not augment the susceptibility of developing this fungal infection.

Risk factors of HIV-related oral lesions in adults
MNMR Petruzzi, K Cherubini, FG Salum… - Revista de Saúde ..., 2013 - SciELO Public Health
The components of cigarette smoke may induce chronic inflammation on the oral mucosae, cause damage to the innate immunity mechanisms against pathogens and inhibit cell growth by apoptosis mechanisms. These effects of smoking reduce the production of salivary enzymes and immunoglobulins and affect the production of lymphocytes, resulting in an imbalance of the oral microflora. These modifications probably encourage EBV infectivity, promoting the occurrence of Oral Hairy Leukoplakia.

Smoking and alcohol consumption contributed to a high susceptibility to the development of these affections in the evaluated subjects.
Dental Recommendations for Treating HIV/AIDS Patients

The magnitude of the viral load is not an indicator to withhold dental treatment for the patient. High viral loads may be present in a patient with early asymptomatic disease, while low viral loads can be seen in very advanced patients on suppressive antiviral therapy. Knowledge of these markers can tell the dentist the general health of the patient and the risk of progression.

The dentist can play an important part in reminding patients of the need for regular follow up and monitoring of these markers. It is recommended that the CD4 and viral load determinants be done every three-six months.
Antibiotic Prophylaxis

There are no data supporting the need for routine antibiotic coverage to prevent bacteremia or septicemia arising from dental procedures. Prophylactic antibiotics should not be prescribed routinely for the dental visit when the HIV infection is well controlled.

**Antibiotic Prophylaxis is Indicated:**

If a patient with a neutrophil count below 500 cells/mm\(^3\) requires procedures likely to cause bleeding and bacteremia and is not already taking antibiotics for prophylaxis against opportunistic infections, consult Pt’s physician regarding the need for antibiotic prophylaxis for dental procedures.
Treatment Considerations

Bleeding tendencies may determine whether or not to recommend full mouth scaling and root planing or multiple extractions in one visit.

In severe cases, patients may be treated more safely in a hospital environment where blood transfusions are available.

Deep block injections should be avoided in patients with a recent history or laboratory results indicating bleeding tendencies.

The ability to withstand treatment for an extended amount of time & the ability to return for sequential visits should be ascertained.

A pre-treatment antibacterial mouth rinse may be indicated.
Treatment Considerations

A three to four month recall schedule should be instituted to monitor any oral changes. For severely immunosuppressed Pts (i.e. CD-4 count of <100), a two to three-month interval should be considered.

Patients exhibiting oral lesions should be assessed in a timely manner.

When reduced salivary function is present, the patient should be closely monitored for caries, periodontitis, soft tissue lesions and salivary gland disease.

Fluoride supplements in the form of a rinse and/or toothpaste should be encouraged for those with increased caries and dry mouth.

A proactive attitude and an emphasis on prevention should encouraged.

Schedule appointments at appropriate times and length based on patient needs.
PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION

1 in 3 primary care doctors and nurses haven’t heard about PrEP.

www.cdc.gov/vitalsigns/HIVPrEP
After exposure to HIV, infection may become established

Postexposure prophylaxis (initiated soon after exposure) reduces the chance of infection

Pre-exposure prophylaxis begins treatment earlier (before exposure), which might increase the prophylactic effect
Pre-Exposure Prophylaxis (PrEP) for HIV Prevention

- Use of antiretroviral meds by *uninfected* patients to **prevent** HIV infection
- Used before and during periods of risk
- Truvada® (tenofovir/emtricitabine) is the only ARV FDA approved for PrEP
  - PrEP efficacy more than 90% for sexually acquired
  - PrEP efficacy more than 70% in IVDU

How do patients take PrEP?

- **Must be taken DAILY**
- PrEP reaches maximum protection from HIV for **receptive anal sex** at about **7 days** of daily use.
- For **all other activities**, including insertive anal sex, vaginal sex, and injection drug use, PrEP reaches maximum protection at about **20 days** of daily use.

http://www.cdc.gov/hiv/basics/prep.html
Thank you

- We are available for clinical consultations and trainings

- Contact Lissette Lahoz
  - lx616@med.Miami.edu

- Dr. Mark Schweizer
  - schweize@nova.edu